The further analysis of DEGs in the high and low CD58 groups within WHO grade II, III, and IV gliomas showed that the differences in the CD2 and CD48 expression between WHO II and III were more pronounced compared to WHO IV, as seen in Figure 3A. Here, CD58 is linked to central nervous system cancer.